期刊
THROMBOSIS AND HAEMOSTASIS
卷 118, 期 9, 页码 1586-1599出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0038-1667015
关键词
BCR-ABL1-negative myeloproliferative neoplasms; JAK2(V617F) mutation; thrombosis; endothelial cells; induced pluripotent stem cells
资金
- INCa (PLBio)
- Novartis
- Lilly Research Programs
Thromboembolic events are the main cause of mortality in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) but their underlying mechanisms are largely unrecognized. The Janus kinase 2 (JAK2)(V617F) mutation is the most frequent genetic alteration leading to MPN. Usually found in haematopoietic progenitors and stem cells, this mutation has also been described in endothelial cells (ECs) of MPN patients. In this study, we have questioned the impact of the JAK2(V617F) mutation on EC phenotype and functions. We developed an induced pluripotent stem cells strategy to compare JAK2 mutant and wild-type ECs. Transcriptomic assays showed that several genes and pathways involved in inflammation, cell adhesion and thrombotic events were over-represented in JAK2(V617F) ECs and expression levels of von Willebrand factor and P-selectin (CD62P) proteins were increased. Finally, we found that leucocytes from MPN patients adhere more tightly to JAK2(V617F) ECs. Our results show that JAK2(V617F) ECs have a pro-inflammatory and pro-thrombotic phenotype and were functionally pro-adherent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据